At the news
? NEUTRALIMPACT 6/10 PRESS-RELEASE filed May 26, 2026 at 16:01 ET
Apogee Therapeutics announced it will release Part B 16-week data from the Phase 2 APEX trial of zumilokibart on May 27, 2026, followed by a conference call. This is a binary catalyst event for the clinical-stage biotech, as zumilokibart is its most advanced program targeting atopic dermatitis, asthma, and eosinophilic esophagitis.
- Part B 16-week data from Phase 2 APEX trial of zumilokibart to be reported on May 27, 2026.
- Conference call and webcast scheduled for 8:00 a.m. ET on May 27, 2026.
- Zumilokibart is Apogee's most advanced program, targeting atopic dermatitis, asthma, and EoE.
- Apogee is a clinical-stage biotechnology company with no approved products or reported revenue.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access